The following video is part of today's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers and Joe Magyer, discuss the latest business news. Shares of Human Genome Sciences doubled today after GlaxoSmithKline made a $2.6 billion bid for the biopharmaceutical company. In this segment, the guys analyze why Glaxo made the bid and why Human Genome Sciences passed it up. They also examine Human Genome Sciences' business to see whether the company just made a mistake walking away from $2.6 billion.
The health-care investing landscape is littered with also-rans and a few major winners. Check out The Motley Fool's free report "Discover the Next Rule-Breaking Multibagger" to learn about a company Motley Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Simply click here -- it's free.
At the time thisarticle was published Chris Hillowns no shares of any of the companies mentioned.Motley Fool newsletter serviceshave recommended buying shares of GlaxoSmithKline. The Motley Fool has adisclosure policy. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.